0.01
0.00%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Imagion Biosystems
Its shares trade on ASX under the ticker IBX.AX. It has been listed since 22 June 2017. In the fiscal year to 31 December 2025, it reported revenue of A$32,370 and a net loss of A$4.3m. At that date it held total assets of A$2.0m and shareholders' equity of −A$2.2m.
Imagion Biosystems Ltd. engages in the research and development of non-radioactive and safe diagnostic imaging technology. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-06-22. The Company’s principal activity consists of nanotechnology, biotechnology, cancer diagnostics, and medical imaging using superparamagnetic relaxometry. The firm operates through Research and Development segment. Its MagSense technology is a functional imaging agent for detecting cancers and other critical diseases. MagSense technology uses bio-safe magnetic nanoparticles that are cancer-specific. MagSense nanoparticles are specially formulated as an injectable solution for each type of cancer. MagSense applications include breast cancer, prostate cancer, and ovarian cancer. The firm is conducting a Phase I clinical study of its MagSense HER2 imaging agent. Its PrecisionMRX nanoparticles have been developed for magnetic relaxometry and other demanding biomedical applications. Its PrecisionMRX products include Dextran-Coated, mPEG Coated, Oleic Acid Coated and Carboxylic Acid Functionalized.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 22 Jun 2017
- Website
- imagionbiosystems.com ↗
Leadership
Pay as last reported
- Mr. Robert ProulxExecutive Chairman of the Board , Managing Director, since 2015A$511,057
- Ms. Yalia JayalakshmiChief Development OfficerA$152,793
- Ms. Melanie LeydinNon-Executive Director, since 2024
- Mr. Brett MitchellNon-Executive Director
- Dr. Nina WebsterNon-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Imagion Biosystems Ltd. develops non-radioactive diagnostic imaging technology in Melbourne, Australia.
- MagSense technology uses bio-safe magnetic nanoparticles for cancer detection in breast, prostate, and ovarian cancers.
- PrecisionMRX nanoparticles offer specialized coatings for magnetic relaxometry applications.
Weaknesses
- Imagion Biosystems Ltd. operates solely in the Research and Development segment with no commercial products yet.
- The company is conducting a Phase I clinical study for MagSense HER2 imaging agent with no market approval.
- Imagion Biosystems Ltd. has no revenue from commercial operations as it is in R&D phase.
Opportunities
- Imagion Biosystems Ltd. can expand MagSense technology applications to additional cancer types beyond breast, prostate, and ovarian cancers.
- The company may leverage PrecisionMRX nanoparticle coatings for new biomedical applications in magnetic relaxometry.
- Imagion Biosystems Ltd. could partner with healthcare providers to advance clinical studies for MagSense HER2 imaging agent.
Threats
- Imagion Biosystems Ltd. faces competition from established diagnostic imaging companies in the Health Care sector.
- The company's reliance on clinical trial success for MagSense HER2 imaging agent poses a significant risk.
- Regulatory approval delays could hinder the commercialization of MagSense technology.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.